Persistent URL of this record https://hdl.handle.net/1887/54935
Documents
-
- Download
- Title Pages_Contents
- open access
-
- Download
- Chapter 2
- open access
- Full text at publishers site
-
- Download
- Chapter 4
- open access
- Full text at publishers site
-
- Download
- Appendices
- open access
-
- Download
- Summary in Dutch
- open access
-
- Download
- Propositions
- open access
In Collections
This item can be found in the following collections:
Toward selective anticancer metallodrugs
The field of transition-metal based chemotherapeutics are dominated by derivatives of cisplatin, but a major downside of these platinum based chemotherapeutics is their lack of selectivity that leads to undesirable side effects. In this work we present alternative strategies such as light-activation with different transition-metals such as ruthenium and palladium that have the potential to be more selective than cisplatin type of drugs.
- All authors
- Rixel, V.H.S. van
- Editor(s)
- Rixel V.H.S. van
- Supervisor
- Bouwman, E.
- Co-supervisor
- Bonnet, S.
- Committee
- Overkleeft, H.S.; Ubbink, M.; Sadler, P.J.; Roelfes, G.J.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Leiden Institute of Chemistry (LIC) , Science , Leiden University
- Date
- 2017-10-19
Funding
- Sponsorship
- NWO